Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Jefferies Remains a Buy on Pfizer (PFE)
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $30 to $36
Pfizer's Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta Setback
Pfizer's Investment Outlook: A Cautious Hold Amid Oxbryta Withdrawal and Mixed Acquisition Results
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $35
Jefferies Sticks to Its Buy Rating for Pfizer (PFE)
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $35
Pfizer (PFE) Receives a Buy From Jefferies
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $36
Pfizer Analyst Ratings
Erste Group Initiates Pfizer(PFE.US) With Hold Rating
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Pfizer Analyst Ratings
Citigroup Adjusts Price Target on Pfizer to $30 From $28, Maintains Neutral Rating
Pfizer Analyst Ratings
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28